27.08

1.39% 0.37

Pre-market: 27.30 0.22 +0.81%

Immunovant Inc (IMVT)

Overview News Price History Option Chain Financials Why IMVT Down? Discussions Forecast

Immunovant Inc stock is traded at $27.08, with a volume of 1.24M. It is up +1.39% in the last 24 hours and up +7.67% over the past month. Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Previous Close:

$26.71

Open:

$26.98

24h Volume:

1.24M

Relative Volume:

0.81

Market Cap:

$5.51B

Revenue:

Net Income/Loss:

$-464.20M

P/E Ratio:

-10.10

EPS:

-2.6823

Net Cash Flow:

$-423.09M

1W Performance:

-0.55%

1M Performance:

+7.67%

6M Performance:

+67.99%

1Y Performance:

+46.46%

1-Day Range:

$26.60

$27.53

1-Week Range:

$26.30

$28.27

52-Week Range:

$12.72

$29.25

Immunovant Inc Stock (IMVT) Company Profile

Name

Immunovant Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

917-410-3120

Address

1000 PARK FORTY PLAZA, DURHAM, NY

Employee

362

Twitter

Next Earnings Date

2025-08-08

Latest SEC Filings

IMVT's Discussions on Twitter

Compare IMVT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMVT Immunovant Inc	27.08	5.44B	0	-464.20M	-423.09M	-2.6823
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Oct-14-25	Initiated	Truist	Hold
Jul-10-25	Resumed	Goldman	Neutral
Mar-03-25	Initiated	Jefferies	Hold
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-10-24	Resumed	Raymond James	Outperform
Oct-09-24	Reiterated	Oppenheimer	Outperform
Mar-28-24	Initiated	Oppenheimer	Outperform
Mar-13-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	JP Morgan	Overweight
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-13-23	Upgrade	UBS	Neutral → Buy
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
May-01-23	Initiated	BofA Securities	Buy
Apr-25-23	Initiated	Citigroup	Buy
Mar-31-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Stifel	Buy
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight
Feb-13-23	Upgrade	Guggenheim	Neutral → Buy
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-26-22	Downgrade	UBS	Buy → Neutral
Dec-08-21	Initiated	Wells Fargo	Equal Weight
Aug-03-21	Downgrade	Robert W. Baird	Outperform → Neutral
Aug-02-21	Downgrade	Credit Suisse	Neutral → Underperform
Jun-01-21	Downgrade	Guggenheim	Buy → Neutral
Jun-01-21	Downgrade	Stifel	Buy → Hold
Oct-28-20	Initiated	UBS	Buy
Oct-12-20	Initiated	Guggenheim	Buy
Oct-08-20	Initiated	Stifel	Buy
Oct-02-20	Initiated	Credit Suisse	Outperform
Aug-26-20	Reiterated	H.C. Wainwright	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Jul-29-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	SVB Leerink	Outperform

View All

Immunovant Inc Stock (IMVT) Latest News

Mar 04, 2026

How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones - simplywall.st

Mar 04, 2026